Finland's Nanoform Q1 revenue rises 45%, EBITDA loss narrows

Nanoform Finland Oyj

19/05/2026 06:19

Overview

Finland nanoparticle engineering firm's Q1 revenue rose 45% yr/yr, gross margin reached 94%

EBITDA loss narrowed as operating costs fell 31%

Company signed first exclusivity deal for biologics technology with US biopharma partner

Outlook

Nanoform targets 2026 cash burn below EUR 10 mln

Company expects first marketing authorization application for a nanoformed medicine to be submitted in 2026

Nanoform anticipates further cost base reduction in coming quarter due to personnel changes

Result Drivers

PROJECT VOLUME - Revenue growth stemmed from increased number of projects, including first exclusivity deal for biologics technology

COST REDUCTIONS - Operating costs fell 31% due to personnel reductions and temporary layoffs, with further impact expected in coming quarters

GROSS MARGIN IMPROVEMENT - Gross margin rose to 94% from 82% yr/yr, contributing to improved profitability

Company press release: ID:nMFN4XWKpZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 1.3 mln
Q1 Gross Margin
94%
Q1 EBITDA
-EUR 3 mln
Q1 Gross Profit
EUR 1.2 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Nanoform Finland Oyj is €2.13, about 138.8% above its May 18 closing price of €0.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)